October 1, 2026 · Enforcement & Compliance
A new federal counterfeit-drug case highlights a practical question for peptide businesses: can you document where your products came from? On September 29, 2026, FDA announced charges against Swapnadip Roy and Vicky Ramancha involving an alleged counterfeit Ozempic distribution scheme. The announcement describes conspiracy and smuggling charges and assistance from FDA’s Office of Criminal Investigations.
What the government alleges
According to FDA’s account of court documents, the defendants allegedly obtained counterfeit Ozempic from unauthorized sources in China between July 2023 and April 2024. Allegedly counterfeit packaging, inserts, pen labels, and needles were designed to mislead downstream customers, including pharmacies and patients. The indictment also alleges deeply discounted sales to U.S. distributors and continued distribution after FDA’s December 2023 seizure and public warning.
These are allegations, not convictions. Both defendants are presumed innocent unless proven guilty beyond a reasonable doubt. The September 2026 announcement concerns alleged conduct from earlier years; it does not establish that every discounted product or peptide supplier is unlawful.
A supply-chain lesson, with important limits
This case concerns allegedly counterfeit finished Ozempic products. It should not be treated as a finding against every compounded formulation or research-use-only peptide. Different products and business models require different legal analyses. Nevertheless, the practical risk is clear: professional-looking packaging and a persuasive supplier are poor substitutes for verified sourcing.
For pharmacies, FDA’s Drug Supply Chain Security Act guidance emphasizes checking trading partners’ licensing or registration, obtaining product-tracing documentation, and retaining that documentation for six years. Pharmacies must also have procedures to quarantine and investigate suspect prescription drugs. Businesses should have counsel determine which requirements and any current exemptions apply to their precise role and products.
Build a review that follows the product
Clinics, medical spas, wellness centers, and chiropractors: Review purchasing authority, supplier credentials, invoices, lot identifiers, shipping conditions, and complaint procedures. Ask who independently verifies a new supplier before the first order. An invoice alone does not resolve authenticity concerns, and possession of a product does not establish authority to prescribe or administer it.
Pharmacies and compounders: Map the actual purchasing and distribution chain. Identify who reviews discrepancies, isolates questionable stock, and communicates with manufacturers and regulators. Keep finished-product sourcing questions separate from the additional ingredient, quality, prescription, and compounding issues counsel must evaluate.
RUO sellers and influencers: Review what you claim about authenticity, origin, testing, and intended use. Avoid suggesting that a laboratory report or supplier certificate answers every legal question. Have a qualified evaluator assess what testing actually establishes, and have counsel review whether advertising or customer communications create unsupported assurances.
Prepare before a questionable shipment arrives
A written escalation plan should identify who can stop distribution, preserve records, and obtain prompt legal advice. FDA states that covered trading partners must notify FDA and appropriate immediate trading partners within 24 hours after determining a product is illegitimate. That determination is different from an initial suspicion; quarantine, investigation, notification, and disposition need a coordinated response.
Retaining a compliance lawyer or qualified regulatory evaluator before a crisis allows the business to test its procedures against real transactions. Preserve supplier messages, invoices, tracing records, and complaints. A useful review identifies gaps, assigns responsibility, and sets correction deadlines; it cannot guarantee immunity.
Request a preliminary peptide-business compliance review. Include your business model, operating states, sourcing process, and any urgent notice or deadline.
General information as of October 1, 2026, not legal advice. Reading or submitting an inquiry does not create an attorney-client relationship; representation requires written acceptance.